United Therapeutics has shown terrific cash profitability, enabling it to reinvest, return capital to investors, and stay ahead of the competition while maintaining an ample cushion. The company ...

A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Commonwealth Equity Services LLC increased its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 3.7% during the fourth quarter, according to the company in its most recent ...

United Therapeutics Co. (NASDAQ:UTHR – Free Report) – Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of United Therapeutics in a ...

United Therapeutics is rated as a BUY due to high financial growth, positive long-term outlook, and current undervaluation despite patent expiration concerns. The company’s revenue is heavily ...

Dr. Baumgartner joins Applied as an accomplished global drug development leader with over 35 years of experience in senior regulatory, clinical development, and medical affairs roles. He has held a ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands ...